Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target

How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to a two-decade-old idea? And how long will Elaine last as a new (official) co-host?

We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.

We also chat about an upcoming presentation from Summit Therapeutics on its cancer drug that beat Merck’s Keytruda, mixed data from Recursion’s lead AI-derived drug candidate, and more news in the life sciences.

For more on amylin obesity drugs, go here; for a detailed preview on Summit’s presentation, go here; for more on Recursion’s mixed results, go here; and to learn more about the full data from Alnylam’s HELIOS-B trial , go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

A rare disease has run through five generations of his family, so he’s built community for others

For Jack Johnson, getting diagnosed with Fabry disease at age 7 was more of a formality. He’d been experiencing symptoms for several years already, and

July 10, 2023

Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer

A recent European Urology Oncology study assessed the mortality risks, based on the Gleason score and clinical parameters, in patients with prostate cancer.

July 11, 2024

Another heat wave is hitting the U.S. Here’s what you need to know

Extreme heat is coming this week in many parts of the United States. The Midwest and Northeast in particular will see weather that puts them

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.